Abstract
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.
Disclosures
Dr Steigbigel receives research support from Merck Research Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, and NexBio Pharmaceuticals. He is on the speakers bureau for Merck, as well as the advisory board for Boehringer Ingelheim. Dr Chirch has no conflicts of interest to declare.